Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.

[1]  B. La Du,et al.  Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[2]  C. Bisgaier,et al.  Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. , 1998, Atherosclerosis.

[3]  P. Belinky,et al.  Structural aspects of the inhibitory effect of glabridin on LDL oxidation. , 1998, Free radical biology & medicine.

[4]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[5]  R. Coleman,et al.  Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[6]  S. Buch,et al.  Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. , 1997, The American journal of clinical nutrition.

[7]  Yasuhiro Watanabe,et al.  Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. , 1997, Biochemical and biophysical research communications.

[8]  M. Odawara,et al.  Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[9]  G. Fonarow,et al.  Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. , 1997, The Journal of clinical investigation.

[10]  E. Topol,et al.  Current Review of Interventional Cardiology , 1997 .

[11]  T. Suehiro,et al.  Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. , 1996, International journal of cardiology.

[12]  B. L. Du,et al.  Structural and functional diversity of paraoxonases , 1996, Nature Medicine.

[13]  P. Edwards,et al.  The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[14]  T. Forte,et al.  Minimally oxidized LDL is a potent inhibitor of lecithin:cholesterol acyltransferase activity. , 1996, Journal of lipid research.

[15]  R. Hegele,et al.  Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins , 1996, Current opinion in lipidology.

[16]  D. Shih,et al.  Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. , 1996, The Journal of clinical investigation.

[17]  P. Shah,et al.  Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA synthesis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[18]  A. Marian,et al.  A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. , 1995, The Journal of clinical investigation.

[19]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[20]  A. Boulton,et al.  Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[21]  G. Charpentier,et al.  Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes , 1995, The Lancet.

[22]  C. Kuo,et al.  Comparison of purified human and rabbit serum paraoxonases. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[23]  O. Lockridge,et al.  Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Durrington,et al.  HDL, its enzymes and its potential to influence lipid peroxidation , 1995 .

[25]  L. Sultatos,et al.  Kinetic mechanism of the detoxification of the organophosphate paraoxon by human serum A-esterase. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[26]  J. Gaziano,et al.  Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human LDL to metal ion-dependent and -independent oxidation. , 1993, Journal of lipid research.

[27]  S. Adkins,et al.  Studies on human serum paraoxonase/arylesterase. , 1993, Chemico-biological interactions.

[28]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[29]  M. Aviram,et al.  Phospholipase A2-modified LDL is taken up at enhanced rate by macrophages. , 1992, Biochemical and biophysical research communications.

[30]  P. Winocour,et al.  Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. , 1991, Atherosclerosis.

[31]  A. Smolen,et al.  PURIFICATION OF HUMAN SERUM PARAOXONASE/ARYLESTERASE , 1991 .

[32]  H. Esterbauer,et al.  A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. , 1989, Journal of lipid research.

[33]  C. Walker,et al.  Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. , 1986, Clinical chemistry.

[34]  B. La Du,et al.  The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. , 1983, American journal of human genetics.

[35]  S. Aust,et al.  Microsomal lipid peroxidation. , 1978, Methods in enzymology.

[36]  O. Lamm,et al.  Enzymatic Hydrolysis of Organophosphorus Compounds. VI. Effect of Metallic Ions on the Phosphorylphosphatases of Human Serum and Swine Kidney. , 1955 .